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INTRODUCTION
Gaucher disease (OMIM 230800, 230900, 231000), the
most common lysosomal storage disorder, is caused by a defi-
ciency in the activity of the enzyme glucocerebrosidase (D-
glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45;
GC). Glucocerebroside or glucosylsphingosine, two substrates
of this enzyme, accumulate in the lysosomes of cells of the
monocyte/macrophage lineage, particularly in the spleen and
liver (1, 2). Clinically, patients with Gaucher disease are divided
into three major phenotypes: chronic nonneuronopathic (type
I); acute neuronopathic (type II); and chronic neuronopathic
(type III), based on symptoms of the nervous system, the severi-
ty of these symptoms, and the age of disease onset (3). The
characteristics of patients with neuronopathic Gaucher dis-
ease include oculomotor abnormalities, hypertonia of the
neck muscles with extreme arching of the neck, bulbar signs,
limb rigidity, seizures and occasional choreoathetoid move-
ments, and neuronal loss (1). However, the mechanisms lead-
ing to the neurological symptoms of this disorder remain
unknown.
In a previous study, we analyzed the mRNA expression pro-
file in the brain of a mouse model for Gaucher disease using
DNA microarrays and found that apoptosis was associated
with neuronal loss (4). Moreover, proinflammatory cytokines
were upregulated in the Gaucher mouse brain. TNF- and
IL-6 mRNA expression levels in the brains of Gaucher mice
were 2.5-fold and 8.5-fold higher than that of wild-type mice,
respectively. This implies that inflammation is associated with
neuronal degeneration in Gaucher disease. There are some
reports of elevated proinflammatory cytokines and sustained
inflammatory reactions in the liver of Gaucher patients and
the Gaucher mouse (5-7). Inflammation has also been reported
in the brains of mouse models for lysosomal storage diseases.
In mouse models of Niemann-Pick type C disease, Tay-Sachs
disease, and Sandhoff disease, activation of microglia and as-
trocytes, and secretion of proinflammatory cytokines, such as
TNF- and interleukin 1 (IL-1 ), are increased (8, 9). More-
over, deletion of the gene for macrophage-inflammatory pro-
tein 1 retards neurodegeneration and extends the lifespan
in a mouse model for Sandhoff disease (10).
In this study, we investigated the levels of proinflamma-
tory cytokines and their possible role in neurodegeneration
in Gaucher mice.
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Upregulation of Proinflammatory Cytokines in the Fetal Brain of the
Gaucher Mouse
Gaucher disease is caused by a deficiency of glucocerebrosidase. Patients with
Gaucher disease are divided into three major phenotypes: chronic nonneurono-
pathic, acute neuronopathic, and chronic neuronopathic, based on symptoms of
the nervous system, the severity of symptoms, and the age of disease onset. The
characteristics of patients with acute neuronopathic- and chronic neuronopathic-
type Gaucher disease include oculomotor abnormalities, bulbar signs, limb rigidity,
seizures and occasional choreoathetoid movements, and neuronal loss. However,
the mechanisms leading to the neurodegeneration of this disorder remain unknown.
To investigate brain dysfunction in Gaucher disease, we studied the possible role
of inflammation in neurodegeneration during development of Gaucher disease in a
mouse model. Elevated levels of the proinflammatory cytokines, IL-1 , IL-1 , IL-6,
and TNF- , were detected in the fetal brains of Gaucher mice. Moreover, the levels
of secreted nitric oxide and reactive oxygen species in the brains of Gaucher mice
were higher than in wild-type mice. Thus, accumulated glucocerebroside or gluco-
sylsphingosine, caused by glucocerebrosidase deficiency, may mediate brain inflam-
mation in the Gaucher mouse via the elevation of proinflammatory cytokines, nitric
oxide, and reactive oxygen species.
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MATERIALS AND METHODS
Mouse care
Glucocerebrosidase-deficient mice (C57BL/6J-Gbatm1Nsb,
‘Gaucher mice’) were obtained from the Jackson Laboratory
(Bar Harbor, ME, U.S.A.). This mouse, which is homozygous
for the GC gene-knockout, expresses <4% of normal GC
activity, stores glucocerebroside in the lysosomes of cells of
the reticuloendothelial system, and dies within a day of birth
(11). All the animals were housed in the Korean Food and
Drug Administration, which is accredited by the American
Association for the Accreditation of Laboratory Animal Care,
and were treated according to the Korean Food and Drug
Administration and National Institutes of Health guidelines
for animal care.
Cell culture
Microglia were prepared from the cerebral cortices of post-
natal ICR-strain mice, and from the brains of wild-type mice
and Gaucher mice (12). Brain tissues, devoid of meninges and
blood vessels, were dissociated by a mild mechanical tritu-
ration. The isolated cells (1×106) were seeded in 75 cm2 T
flasks in MEM medium (Life Technologies, Grand Island,
NY, U.S.A.) containing 10% heat-inactivated fetal bovine
serum, for two weeks. Microglia were then detached from
the flasks by mild shaking and seeded in plates with or with-
out 200  M conduritol B epoxide (CBE; Sigma, St Louis,
MO, U.S.A.), a specific GC inhibitor (13), at 37℃ in a 5%
CO2 incubator for 8 days.
Semiquantitative reverse transcriptase-polymerase chain
reaction (RT-PCR)
Fetal brains of postnatal wild-type mice and Gaucher mice
were separated into cerebral cortex, brainstem, and cerebel-
lar regions. Total RNA was isolated using an RNeasy Mini
kit (Qiagen GmbH, Germany). Reverse transcriptase (RT)
reactions were performed with 2  g of total RNA using 50
g/mL of oligo (dT) primer at 42℃ for 1 hr in the presence
of 20 units of MMLV RT (Promega, Madison, WI, U.S.A.).
Aliquots of the RT product were amplified by polymerase
chain reaction (PCR) using 20 cycles of 94℃for 45 sec, 60℃
for 30 sec, and 72℃for 30 sec. The PCR cycles were performed
in a reaction volume of 25  L, including 2  L RT products
as a template, 1×reaction buffer, 1 unit of Ex Taq DNA poly-
merase (TaKaRa, Japan), and 20 pmol of each primer. Primer
sequences were as follows:  -actin, forward 5′ -CCCACAC-
TGTGCCCATCTAC-3′ , reverse 5′ -AGTACTTGCGCTC-
AGGAGGA-3′ ; IL 1 , forward 5′ -CGTCAGGCAGAAG-
TTTGTCA-3′ , reverse 5′ -GTGCACCCGACTTTGTTC-
TT-3′ ; IL 1 , forward 5′ -CAGGCAGGCAGTATCACTC-
A-3′ , reverse 5′ -AGGCCACAGGTATTTTGTCG-3′ ; IL
6, forward 5′ -GTTCTCTGGGAAATCGTGGA-3′ , reverse
5′ -GGAAATTGGGGTAGGAAGGA-3′ ; and TNF- , for-
ward 5′ -ACGGCATGGATCTCAAAGAC-3′ , reverse 5′ -
CGGACTCCGCAAAGTCTAAG-3′ . The PCR products
were analyzed on 1% agarose gels.
Detection of cytokines
To measure cytokines secreted from microglial cells, we
used the Beadlyte Mouse Multi-Cytokine Detection System
2 (Upstate, Lake Placid, NY, U.S.A.) following the manufac-
turer’s instructions. Fifty microliter aliquots of media from
cultured microglia were loaded into 96-well microplates with
25  L of Luminex bead-conjugated anti-mouse multi-cytokine
antibody. Two hours later, 25  L of biotin-conjugated anti-
mouse multi-cytokine antibody was added to each well. After
incubation for 1.5 hr, 25  L of streptavidin-phycoerythrin
solution was added. After 30 min, 25  L of stop solution was
added. Samples were analyzed using a Luminex 100 lumi-
nometer (Luminex, Austin, TX, U.S.A.).
Determination of nitric oxide and reactive oxygen species
The amount of nitric oxide (NO) produced from microglia
of wild-type mice and Gaucher mice was determined using
the Griess method (14). Using 96-well cell culture plates,
each well was filled with 100  L of MEM medium mixed
with an equal volume of Griess reagent (0.1% naphthylethy-
lenediamine, 1% sulfanylamide, 2.5% H3PO4). After 10 min
at room temperature, the optical density of samples was mea-
sured using a microplate reader at 550 nm. To measure intra-
cellular reactive oxygen species (ROS) production, cells iso-
lated from wild-type and Gaucher mouse brains were load-
ed with 10  M 5,6-chloromethyl-2′ , 7′ -dichlorodihydroflu-
orescein diacetate acetyl ester (CM-H2DCFDA, Molecular
Probes, Eugene, OR, U.S.A.) for 30 min at room tempera-
ture in the dark. The cells were then washed, resuspended
in phosphate buffered saline and analyzed on a flow cytome-
ter (FACS Vantage, BD, Franklin Lakes, NJ, U.S.A.) equipped
with a 488 nm argon-ion laser and a 525 nm bandpass emis-
sion filter.
Statistical analysis
The statistical significance of differences between groups
was determined using Student’s t-test. The data are present-
ed as mean±SD.
RESULTS
Genes for the cytokines IL-1 , IL-1 , IL-6, and TNF-
were upregulated in the cerebral cortex, brainstem, and cere-
bellum of Gaucher mice compared with those of wild-typeCytokines in the Brain of Gaucher Mouse 735
mice by RT-PCR (Fig. 1A). We induced Gaucher disease in
a cell model using primary cell cultures of microglia from
ICR-strain mice. After incubation with 200  M CBE for 8
days, IL-6 and TNF- mRNAs were upregulated in CBE-
treated microglia (Fig. 1B). However, there was no increase
in IL-1 or IL-1 mRNA levels (data not shown). Using the
Beadlyte Mouse Multi-Cytokine Detection System 2, which
can detect 10 cytokines (MG-CSF, IFN- , IL-1 , IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12 and TNF- ), we analyzed cytokine
levels in CBE-treated microglia. Three of them were detectable
and secreted at high levels from CBE-treated microglia (Fig.
1C). The mean level of secreted IFN- was 2.2-fold greater
in CBE-treated microglia (35.3±5.3 pg/mL) compared with
control microglia (16.2±5.9 pg/mL). The amount of secret-
ed IL-6 was 1.8-fold higher in CBE-treated microglia (219.5
±49 pg/mL) compared with control microglia (125.8±9.9
pg/mL), and the level of TNF- secreted from CBE-treated
microglia (183.8±25.2 pg/mL) was 2.8-fold higher com-
pared with control microglia (65.3±4.1 pg/mL).
Cells from the cerebral cortex, brainstem, and cerebellum
of Gaucher mice produced 4.04±0.19  M NO, 4.31±0.18
M NO, and 3.78±0.20  M NO, respectively. The same
tissues from wild-type mice produced 2.57±0.09 M  NO,
2.58±0.15  M NO, and 3.03±0.17  M NO, respective-
ly (Fig. 2). Thus, the level of production of NO in cells of
Gaucher mice was 1.25-fold higher in the cerebellum (p<
0.01) and 1.67-fold higher in the brainstem (p<0.001) com-
pared with NO production in the corresponding cells of wild-
type mice.
ROS generation in microglial cells of the mouse brain was
analyzed using flow cytometry (Fig. 3). Microglial cells from
the brainstem and cerebellum of Gaucher mice had higher
levels of ROS compared with microglial cells from the brain-
stem and cerebellum wild-type mice at embryonic day 19.5
(E19.5) and postnatal day 1 (P1). However, there was no dif-
ference in ROS levels in cells from the cerebral cortex of wild-
type mice and Gaucher mice.
DISCUSSION
Gaucher disease is mainly caused by the accumulation of
glucocerebroside, a metabolic intermediate in the synthesis
and degradation of complex glycosphingolipids. This causes
the release of calcium from intracellular stores, leading to
enhanced sensitivity to agents that induce neuronal death
(13, 15). The deacylated analog of glucocerebroside, gluco-
sylsphingosine, accumulates in the cerebral and cerebellar
cortices of patients with type II and type III Gaucher disease
(16), and in the brains of Gaucher mice (17), and has been
suggested to be a candidate neurotoxin (18, 19). However,
no explanation has yet been proposed to link these experi-
mental results to the known neurodegenerative symptoms
of Gaucher disease (20).
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Fig. 1. RT-PCR analysis of IL-1 , IL-1 , IL-6 and TNF- mRNA expression in mouse brains (A) and of IL-6 and TNF- mRNA expression
in cultured microglia with or without 200  M of CBE (conduritol B epoxide; see Materials and Methods) (B). Cytokines secreted from cul-
tured microglia were analyzed (C): Open bar, untreated microglia; closed bar, microglia treated with 200  M of CBE for 8 days. W-Cx,
cerebral cortex of wild type mouse; G-Cx, cerebral cortex of Gaucher mouse; W-Bs, brainstem of wild type; G-Bs, brainstem of Gaucher
mouse; W-Cbll, cerebellum of wild type; G-Cbll cerebellum of Gaucher mouse..
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Fig. 2. NO release from cultured brain cells of cerebral cortex, bra-
instem and cerebellum. Open bars, NO levels from cells of wild
type mice; closed bars, NO levels from cells of Gaucher mice. *p<
0.01, 
� p<0.001 vs. wild type mice (by paired t tests).
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Gaucher disease is characterized by the accumulation of
glucosylceramide in macrophages and macrophage-derived
cells in various tissues (3). Among the earliest and more pro-
vocative suggestions to explain phenotypic variability in Gau-
cher disease was the suggestion that it is an immune or auto-
immune reaction to a chronic storage of glucocerebroside (21).
Systemically, an excessive immune response involves the inhi-
bition of proinflammatory cytokines, such as TNF- , which
is produced by macrophages and is necessary for adhesion
molecule expression and leukocyte recruitment to inflamma-
tory sites (22).
Inflammation is an important contributor to neuronal da-
mage in other neurodegenerative conditions, such as Parkin-
son’s disease, Alzheimer’s disease, multiple sclerosis, and amyo-
trophic lateral sclerosis (23-25). One of the best-known fea-
tures of inflammation in the central nervous system (CNS)
is the production of NO, which is a product of macrophages
that have been activated by cytokines and a microbial com-
pound found in the inflammatory reaction (26). Lipopolysac-
charide, IFN- , TNF- , and IL-1 are responsible for microglial
activation and NO production (27). Production of NO is
associated with the generation of ROS, including superoxide
anions, hydroxyl radicals, lipid hydroperoxides, and hydro-
gen peroxide. These compounds are toxic to neurons because
they induce lipid peroxidation, DNA fragmentation, and
protein oxidation (28, 29). Moreover, ROS can activate pro-
tein kinase C, mitogen-activated protein kinase, and nuclear
factor-kappa B, which regulate the expression of genes encod-
ing a variety of proinflammatory factors (30, 31). Inflamma-
tion-mediated neurodegeneration has received considerable
attention in lysosomal storage diseases. In mouse models of
Sandhoff disease and Tay-Sachs disease, genes associated with
the activation of microglia and astrocytes are overexpressed,
and progressive CNS inflammation correlates with the sever-
ity of disease (32, 33).
We could not observe the inflammatory reaction in the
fetal brains of Gaucher mice because this mouse model does
not survive longer than one day after birth (11). Therefore,
we examined the fetal brains of Gaucher mice and explored
the accumulation of glucosylceramide in microglia, which
could be a causative factor of inflammation related to neu-
rodegeneration.
In this study, the secretion of proinflammatory cytokines
increased in the brains of Gaucher mice and in CBE-treated
microglia, a cell model of Gaucher disease. We examined
whether the upregulation of proinflammatory cytokines result-
ed in the production of NO and found increased production
of NO in the brain cells of Gaucher mice. Increased ROS
generation in microglial cells from the brainstem and cere-
bellum of Gaucher mice also occurred. Thus, a deficiency of
GC activity may mediate microglial activation resulting in
the production of cytokines, NO, and ROS.
Further in vivo approaches to understanding the patho-
physiology of Gaucher disease and the development of new
therapeutic strategies for Gaucher disease have been hindered
by the lack of a viable animal model (11, 34). However, the
generation of viable mouse models of Gaucher disease has
recently been reported (35), and these mouse models will be
useful for elucidating the pathogenesis of the neuronopathic
forms of Gaucher disease.
Although we have no direct evidence that the overexpres-
sion of proinflammatory cytokines or the production of NO
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Fig. 3. Detection of ROS with CM-H2DCFDA (see Materials and methods) in the microglial cells of cerebral cortex (A and D), brainstem
(B and E) and cerebellum (C and F) from wild type mice (n=3, dotted line) and Gaucher mice (n=3, solid line). Upper panel, cells from
day E19.5 embryos; lower panel, cells from day P1 neonates.
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FL1-H Fand ROS are involved in the neurodegenerative symptoms
of Gaucher disease, further investigation of the relationship
between microglial activation and the accumulation of GC
substrates should clarify the roles of these factors.
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